Tarsus Pharmaceuticals, Inc.
TARS
Pozycja w akcjach
#4589
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Cena akcji
$71.12
Kapitalizacja rynkowa
$3.33B
Zmiana (1 dzień)
2.33%
Zmiana (1 rok)
-0.10%
Kraj
US
Handel Tarsus Pharmaceuticals, Inc. (TARS)
Kategoria
Healthcare
Wskaźnik P/B dla Tarsus Pharmaceuticals, Inc. (TARS)
Wskaźnik P/B na dzień October 2026 TTM: 9.05
Według najnowszych raportów finansowych i ceny akcji Tarsus Pharmaceuticals, Inc., obecny wskaźnik P/B (TTM) wynosi 9.05. Na koniec 2023 wynosił 3.02.
Historia wskaźnika P/B dla Tarsus Pharmaceuticals, Inc. od 2018 do 2026
Wskaźnik P/B na koniec każdego roku
| Rok | Wskaźnik P/B | Zmień |
|---|---|---|
| 2026 (TTM) | 9.05 | -2.40% |
| 2024 | 9.27 | 207.02% |
| 2023 | 3.02 | 61.44% |
| 2022 | 1.87 | -32.54% |
| 2021 | 2.77 | -45.19% |
| 2020 | 5.06 | -107.57% |
| 2019 | -66.86 | 2.65% |
| 2018 | -65.13 | 0.00% |
Wskaźnik P/B dla podobnych firm lub konkurentów
| Firma | Wskaźnik P/B | Różnica wskaźnika P/B | Kraj |
|---|---|---|---|
| 6.251 | -30.91% |
US
|
|
| 13.2547 | 46.51% |
US
|
|
| 4.208 | -53.49% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -31.66% |
NL
|
